Datasheet

Version: 1.0.0 Revision date: 16 Feb 2024



Lenvervimab

Catalogue No.:abx831469

Lenvervimab is a monoclonal antibody biosimilar expressed in CHO cells, targeting HBV, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications.

Lenvervimab (GC1102) is a recombinant hepatitis B immunoglobulin developed by the Korean biopharmaceutical company GCPharma, which aims to reduce the blood HBsAg level to improve the continuous virological response, thereby enhancing the therapeutic effect.

Target: HBV

Clonality: Monoclonal

Reactivity: Human

Expression: Recombinant

Tested Applications: ELISA, WB

Host: Human

Recommended dilutions: Optimal dilutions/concentrations should be determined by the end user.

Conjugation: Unconjugated

Isotype: IgG₁ Kappa

Form: Liquid

Purity: > 95%

Purification: Purified from cell culture supernatants by Protein A/G chromatography.

Storage: Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles.

Buffer: 0.01 M PBS. pH 7.4.

CAS Number: 2055006-79-4

Concentration: Batch-dependent, typically between 0.5-2.0 mg/ml.

Note: This product is for research use only.

Not for human consumption, cosmetic, therapeutic or diagnostic use.